Citation: Ward J, Hamill P, “The Hidden Risks in Drug-Device Delivery: Why the Final Stage Defines Launch Success”, ONdrugDelivery Online, July 6th, 2026
John Ward and Paul Hamill explore the structural and operational risks embedded in late-stage drug-device delivery, why these risks are intensifying and how the industry is beginning to rethink its approach to downstream execution.
When it comes to developing drug-device combination products, the pharmaceutical industry’s attention is often understandably concentrated on early-stage innovation, not least molecule discovery, formulation science, device engineering and clinical validation. These phases are complex, high-risk and resource intensive. However, there is a persistent, often underestimated reality within the pharmaceutical industry – many of the most consequential risks to product launch success emerge much later, in the final stages of the value chain.
From post-fill-finish handling through to cleanroom final assembly, packaging and market release, the downstream segment of drug-device delivery represents a convergence point for complexity, compliance and commercial urgency. It is at this stage, closer than any other to the point of care, that small disruptions can cascade into major delays, regulatory challenges or even supply failures.
THE OVERLOOKED CRITICAL PATH
In traditional pharmaceutical development models, downstream activities, such as final assembly, labelling, packaging, sterilisation management and release preparation, have often been viewed as executional rather than strategic. Compared with formulation or device design, they have historically been perceived as more predictable, or even commoditised. That perception is increasingly out of step with on-the-ground realities.
“At this stage, there is little room for adjustment. Timelines are tightly aligned to launch commitments, and the ability to absorb disruption is minimal. In effect, downstream operations become the critical path for commercialisation.”
Modern drug-device combination products, including autoinjectors, prefilled syringes and on-body delivery systems, require precise integration between drug and device components. This integration often spans multiple suppliers, geographies and regulatory frameworks. By the time a product reaches post-fill-finish, it reflects the accumulated variability of every upstream process. At this stage, there is little room for adjustment. Timelines are tightly aligned to launch commitments, and the ability to absorb disruption is minimal. In effect, downstream operations become the critical path for commercialisation.
LATE-STAGE BOTTLENECKS: A SYSTEMIC CHALLENGE
Several structural pressures can converge to make late-stage bottlenecks more pronounced and more difficult to manage. These pressures interact in ways that compound risk. Key drivers include the following factors.
Capacity Constraints Driven by Market Dynamics
The rapid growth of biologics and, more recently, the surge in glucagon-like peptide-1 (GLP-1) therapies have placed unprecedented strain on manufacturing networks. While much attention has focused on fill-finish capacity, downstream operations are under pressure as well. Large CMOs and CDMOs are increasingly optimised for high-volume production, creating a structural gap for low- to mid-volume programmes, such as rare diseases, orphan drugs, clinical trial materials and early commercial launches, that require flexibility rather than scale. These programmes often struggle to secure appropriate capacity, leading to scheduling delays and reduced optionality.
High-Mix, Low-Volume Complexity
Unlike blockbuster products with standardised configurations, many modern therapies require high-mix production – multiple stock keeping units (SKUs), regional variations and differing labelling requirements and instructions for use (IFUs). Managing this complexity in the final assembly and packaging stages introduces operational risk. Changeovers, line clearance, documentation control and quality assurance processes become more intricate, increasing the likelihood of errors or inefficiencies.
Serialisation and Regulatory Divergence
Global regulatory requirements for serialisation, traceability and anti-counterfeiting measures add another layer of complexity. Compliance is not uniform across markets, as requirements differ in terms of data structure, reporting and aggregation. Integrating serialisation into late-stage packaging operations while maintaining throughput and accuracy requires robust digital infrastructure and tightly controlled processes. Any misalignment can delay batch release or market entry.
Cold Chain and Logistics Integration
For the growing wave of temperature-sensitive biologics, downstream operations must also be tightly integrated with cold-chain logistics. Packaging design, material selection and distribution planning can all influence product stability. Disruptions or miscalculations at this interface can compromise product integrity, necessitating rework or, in worst-case scenarios, resulting in product loss.
THE POST-FILL-FINISH PARADOX
Fill-finish is often viewed as the final major manufacturing milestone, however, in practice, it marks the beginning of a new phase of complexity rather than the end of production. Once the drug product has been filled, it must still pass through a series of tightly controlled downstream processes before it is ready for patients. These include assembly into the final delivery device (where applicable), inspection, labelling, packaging and, ultimately, release.
“This creates a paradox. Although the product is complete from a formulation perspective, it is not yet ready for market, and the path to readiness is both operationally demanding and highly sensitive to disruption.”
Each step here is governed by strict regulatory requirements and often involves co-ordination across multiple sites or partners. This creates a paradox. Although the product is complete from a formulation perspective, it is not yet ready for market, and the path to readiness is both operationally demanding and highly sensitive to disruption.
The interdependency of components becomes particularly evident at this stage – device parts, packaging materials and labelling assets must all align perfectly, and delays in any one element can halt progress. Simultaneously, timelines are compressed. Batch release depends on synchronised documentation, quality checks and regulatory compliance, leaving little room for slippage. Compounding this is the fact that inventory buffers are often minimal, especially for high-value biologics, limiting manufacturers’ ability to absorb unexpected delays.
WHY THE FINAL STAGE DEFINES LAUNCH SUCCESS
Post-fill-finish assembly, packaging and release activities sit at this critical juncture, where execution directly determines whether or not a product reaches patients on time. Several factors explain why this stage has such a disproportionate influence on launch outcomes, the combination of which makes downstream execution not just operationally important, but strategically decisive.
Time-to-Market Sensitivity
Delays in early development phases, while costly, can often be managed within broader project timelines. In contrast, delays in final assembly and packaging directly impact launch dates. Put simply, there is less runway for adjustment or catch up during the final stages of production. For products targeting competitive therapeutic areas, even a short delay can have significant commercial implications. First-mover advantage may be lost, or market share eroded.
Regulatory Exposure
Regulatory scrutiny intensifies as products approach release. Documentation must be complete, traceable and audit-ready. Any discrepancies identified at this stage can trigger investigations, batch rejections or additional validation requirements.
Supply Chain Continuity
Downstream operations are the final checkpoint before distribution. Failures here can disrupt supply chains, leading to stockouts or delayed availability in key markets.
Financial Implications
The cost of failure increases exponentially as a product moves through the manufacturing lifecycle. Late-stage disruptions can result in wasted product, expedited logistics costs and contractual penalties, in addition to lost revenue.
THE CASE FOR SPECIALIST DOWNSTREAM EXPERTISE
Given the concentration of risk and complexity in the final stages of production, there is growing recognition that downstream operations require dedicated expertise. Treating them as an extension of upstream manufacturing is increasingly seen as over-simplification.
Specialist partners in this space tend to focus exclusively on post-fill-finish activities, bringing with them a different operational model. Rather than being optimised for large-scale, standardised production, these organisations are often structured to handle variability, supporting lower volumes, higher mix and more complex configurations. This flexibility can be critical when timelines shift or requirements evolve, which is common in the late stages of development. The ability to adapt without compromising quality or compliance becomes a defining capability.
Equally important is the integration of services. Final assembly, packaging, labelling, serialisation and release preparation are closely interdependent processes, and managing them within a cohesive framework can reduce handoffs and improve efficiency. When these activities are fragmented across multiple providers, co-ordination risk increases.
Regulatory and quality expertise also play a central role. Operating across different markets requires a nuanced understanding of local requirements, and maintaining compliance across jurisdictions is a non-trivial challenge. Providers with established regulatory and quality infrastructures are better positioned to navigate this complex environment.
Finally, the infrastructure required to support high-mix production and serialisation, particularly digital systems and data management capabilities, has become a key differentiator. Without these systems, maintaining accuracy and traceability at scale becomes increasingly difficult.
“The result is a structural bottleneck, where viable products face delays not because of scientific or clinical barriers, but because of a mismatch in manufacturing capacity and capability. Addressing this gap requires a different approach that values flexibility and scalability alongside efficiency.”
ADDRESSING THE MID-VOLUME GAP
One of the more subtle but significant challenges in the current landscape is the gap between clinical-scale manufacturing and large-scale commercial production. Products in early commercialisation or targeting smaller patient populations often fall into the “mid-volume” category. They are too large for clinical facilities yet too small to be prioritised by manufacturers focused on high-volume output. This dynamic is particularly relevant for rare diseases, specialised biologics and market expansion efforts.
The result is a structural bottleneck, where viable products face delays not because of scientific or clinical barriers, but because of a mismatch in manufacturing capacity and capability. Addressing this gap requires a different approach that values flexibility and scalability alongside efficiency. It also reinforces the importance of aligning manufacturing strategy with the product lifecycle stage, rather than applying a one-size-fits-all model.
THE IMPORTANCE OF EARLY ALIGNMENT
Although downstream activities occur late in the manufacturing lifecycle, their success is often determined by decisions made much earlier in development. Decisions made during device design, packaging development and supply chain planning can either enable or constrain downstream execution.
Without early alignment, issues such as manufacturability, regulatory compliance or component compatibility may only become apparent at a stage when changes are costly and disruptive. In some cases, this can lead to packaging redesigns late in the programme, delays to validation activities or the need to repeat stability or transport testing. A seemingly minor issue, such as an incompatibility between a device component and a packaging format, can ultimately delay release timelines by weeks or even months.
Regulatory complexity can also escalate quickly when downstream considerations are introduced too late. Market-specific labelling, serialisation requirements or cold-chain constraints may require additional process changes or documentation and regulatory filing updates at the point closest to launch, where timelines are least flexible. For companies working towards a planned commercial launch, these delays can have direct financial consequences, disrupt supply continuity and create knock-on effects across distribution and market access plans.
“Market-specific labelling, serialisation requirements or cold-chain constraints may require additional process changes or documentation and regulatory filing updates at the point closest to launch, where timelines are least flexible.”
Engaging downstream expertise earlier in the process can help mitigate these risks. This does not require a fundamental shift in development models, but rather a more integrated perspective that recognises that the final stages are not isolated but intrinsically linked to upstream decisions.
A SHIFT IN INDUSTRY MINDSET
The increasing complexity of drug–device combination products is driving a broader shift in how the pharmaceutical industry views the final stages of delivery. Rather than being treated as a linear endpoint, downstream operations are now increasingly being recognised as a critical, specialised discipline requiring dedicated focus. This shift is reflected in several emerging trends:
- Decoupling of Upstream and Downstream Partnerships: Companies are selecting different partners for development/manufacturing and for final assembly/packaging, based on specific expertise.
- Greater Emphasis on Supply Chain Orchestration: Co-ordinating multiple suppliers and processes is becoming a core competency.
- Investment in Digitalisation: Serialisation, traceability and data integration are central to downstream efficiency.
- Focus on Resilience: Flexibility and redundancy are being built into supply chains to manage uncertainty.
WHERE LAUNCH SUCCESS IS TRULY DECIDED
In the lifecycle of drug-device combination products, the final stages are where complexity converges and risk becomes most acute. Despite their proximity to patient delivery, these stages have historically received less strategic attention than earlier phases of development. That imbalance is becoming increasingly unsustainable.
Late-stage bottlenecks, post-fill-finish complexity and capacity constraints are exposing vulnerabilities that can undermine even the most carefully managed development programmes. As therapies become more sophisticated and timelines more compressed, the importance of downstream excellence will only continue to grow. Recognising the final stage as a defining factor in launch success and planning for it accordingly will be essential for companies seeking to deliver reliably in an increasingly demanding environment.
